11 points (advantages) that you should consider seriously for making Whole Genome Sequencing the first line diagnostic genetic test: 1) Reporting deep intronic Pathogenic/Likely Pathogenic variants 2) CNVs analysis with detection limit at the exon level 3) Mitochondrial genes mutations at heteroplasmy levels down to 1% 4) PRS analysis for Breast Cancer using the CanRisk Algorithm of Cambridge which is recommended by ACMG. (Performing NGS analysis for Breast Cancer you could have an actionable report ONLY to 10% of examined ladies. With PRS you could have an actionable report at the 100% of these ladies. see reference at the end) 5) Implementation of more than 500 PRS algorithms in more than 200 traits (this feature will be available soon) 6) Complete PGx report (medications and indications related to PGx mutations 7) Dedicated Thromvophilia report (special use during pregnancy) 8) Genetic counseling and clinical report related to the described phenotype 9) FASTQ raw data available for download 10) Reanalyis every 6-8 months in case of undiagnosed severe diseases 11) Price and TAT: WGS, PCR-Free, 690€ reduced price valid up to 21-12-2021, TAT 4-6 weeks Reference: See in the link bolow why PRS for breast cancer is the preferable genetic test https://lnkd.in/gSNH7Bza For further information please contact us Neoscreen Laboratory
Σχετικά με εμάς
Neoscreen was founded in 2007 and it is involved in the development and application of genetics test regarding prenatal testing, carrier screening (testing for future parents), hereditary cancer syndromes, congenital heart diseases, pharmacogenomics profiling (effect of genotype on drug response) as well as expanded neonatal screening. In addition, Neoscreen offers whole genome sequencing as a diagnostic tool for serious diseases. Since its establishment it collaborates with private hospitals (IASO, IASO Thesallia, REA, GAIA, EUROPEAN INTERBALKAN MEDICAL CENTER), In Vitro Fertilization (IVF) centers, doctors, stem cell companies (Omnigen), the Breast Center in Ippokrateio Hospital under the direction of Professor Mr. G.Zografos, with EKKAN, the Congenital Heart Diseases Center in Ippokrateio Hospital under the direction of Dr. A. Anastasakis and professor Mr. X. Stefanades, providing services of high quality. A total of more than 80.000 newborns have been subjected to Neonatal Testing and more than 7.000 adults per year are being subjected to genetic tests (for Cystic Fibrosis, Thrombophilia, Thalassemia, Spinal Muscular Atrophy, BRCAs, Hypertrophic cardiomyopathy, Whole Exome Sequencing etc.). Neoscreen employs high level personnel and owns equipment of the latest technology. The most of our tests are accredited by the Hellenic Accreditation System (E.SY.D.) according to the international standards ISO 17025 & ISO 15189. As part of the accreditation, it is subjected to external quality control by the CDC (Center for Disease Control & Prevention) and the Instant eV, with 100% success.
- Ιστότοπος
-
https://neoscreen.online/
Εξωτερικός σύνδεσμος για τον οργανισμό Neoscreen Medical Ltd
- Κλάδος
- Wellness and Fitness Services
- Μέγεθος εταιρείας
- 11-50 εργαζόμενοι
- Έδρα
- Vrilissia
- Τύπος
- Ιδιωτική κατοχή
- Ειδικότητες
Τοποθεσίες
-
Κύρια
Οδηγίες πλοήγησης
Voreiou Ipeirou
Vrilissia, GR